Inhaled Heparin: An Old Anticoagulant Emerging as a New Weapon Against Severe Respiratory Infections
Click here to hear in youtube: https://youtu.be/rkoadbbckTY
References
van Haren FMP, Valle SJ, Serpa Neto A, et al. Efficacy of inhaled nebulised unfractionated heparin to prevent intubation or death in hospitalised patients with COVID-19: an international meta-trial. eClinicalMedicine. 2025.
“Doctors tested a common drug on COVID. The results are stunning.” ScienceDaily. September 28, 2025.
Dixon B, et al. Nebulised heparin in acute lung injury: systematic review and meta-analysis. Lancet Respir Med. 2020.
Glas GJ, et al. Nebulised heparin for patients under mechanical ventilation. Ann Intensive Care. 2016.
Li X, et al. Low-molecular-weight heparin treatment in ALI/ARDS: a systematic review and meta-analysis. Int J Clin Exp Med. 2018.
NIH COVID-19 Treatment Guidelines. Updated 2025.
Evidence Summary
In late September 2025, the global conversation around COVID-19 shifted with the publication of a multinational meta-trial on inhaled unfractionated heparin. Coordinated from Melbourne and reported in eClinicalMedicine, the trial aggregated over 500 hospitalized patients across six countries. The findings, highlighted by ScienceDaily, were striking: patients treated with nebulized heparin had nearly half the risk of progressing to mechanical ventilation or dying compared to those on standard care. This was not a marginal statistical fluctuation — it was a structural signal, one that forces clinicians, regulators, and policymakers to reconsider the therapeutic arsenal against COVID-19.
Why did this result matter so much? Because it emerged in a landscape of partial solutions. Antivirals like remdesivir and nirmatrelvir/ritonavir reduce viral replication, but only if given early and often with limited effect in severe cases. Corticosteroids, such as dexamethasone, can blunt inflammation but do so by suppressing immune defenses, risking secondary infections. Immunomodulators like tocilizumab offer targeted relief for cytokine storms but are expensive and not universally accessible. Systemic anticoagulation reduces thrombotic complications but at the cost of bleeding risk, particularly in fragile patients. And supportive care — oxygen, high-flow devices, non-invasive ventilation, and intubation — remains the final recourse, resource-intensive and unequally distributed across the globe.
Against this fragmented therapeutic background, inhaled heparin appears different. It is not a new molecule; it is a century-old drug, inexpensive, stockpiled, and familiar to clinicians everywhere. Its innovation lies in its delivery. Nebulization concentrates the drug where the pathology resides — the lungs — while minimizing systemic exposure. The molecule’s pleiotropy is its strength: it prevents microthrombosis, tempers inflammation, protects the endothelial barrier, and may even act as a viral decoy by binding SARS-CoV-2 spike proteins. Unlike antivirals that address replication alone, or steroids that mute immunity broadly, inhaled heparin speaks the multiple languages of COVID pathophysiology simultaneously.
Historical evidence reinforces this plausibility. Dixon’s 2020 review had already shown that inhaled heparin improved oxygenation and reduced markers of lung injury in ARDS. Glas and colleagues demonstrated its safety in mechanically ventilated patients nearly a decade earlier. Li’s meta-analysis suggested that LMWH could improve survival in acute lung injury, even without inhalation. These strands of data, once peripheral, now converge under the lens of COVID.
The broader narrative is just as compelling. Five years into the pandemic, COVID has not vanished; it has evolved into a slower, endemic burn, dominated today by Omicron descendant NB.1.8.1. Vaccines and antivirals still matter, but health systems remain vulnerable to seasonal surges and the constant churn of sublineages. In this context, a low-cost, multi-pathway therapy that reduces intubation and death carries weight far beyond statistical endpoints. It becomes a tool of medical sovereignty, especially for low- and middle-income countries unable to compete for monoclonal antibodies or advanced ICU technology.
The story of inhaled heparin is therefore not just about efficacy. It is about architecture: the possibility that global pandemic response could pivot away from exclusivity-driven biologics toward intelligent repurposing of generics. The trial’s results are an opening chapter, not a conclusion. Phase III studies are urgently needed, safety data must be expanded, and regulators must prepare adaptive frameworks. But the symbolic shift has already begun: a reminder that sometimes the most disruptive therapies are not the newest, but the most cleverly redeployed.
Five Laws Structure
Law of Shock / Hook
Patients treated with inhaled heparin had roughly half the risk of requiring mechanical ventilation or dying compared to standard care.
This opening frames the discovery as an immediate paradigm shift.Law of Context
Current therapies for severe COVID-19 and respiratory infections are limited: antivirals have mixed efficacy, systemic anticoagulation carries risks, and ICU-level care is resource-intensive. Many low- and middle-income countries cannot afford advanced biologics or prolonged ventilation. In this context, a cheap and widely available drug like heparin, if reformulated for inhalation, could be transformative.Law of Mechanism / Explanation
Inhaled heparin acts through multiple pathways:Anticoagulant: prevents pulmonary microthrombosis.
Anti-inflammatory: reduces cytokine-driven lung damage.
Antiviral potential: blocks viral entry or replication by binding viral proteins.
Delivery by nebulization concentrates effects in the lungs while minimizing systemic bleeding risk, a crucial safety advantage.
Law of Implications / Consequences
For patients: a low-cost, adjuvant therapy that could improve survival in severe respiratory infections.
For public health: rapid deployment in pandemics and seasonal surges, especially in resource-limited settings.
For industry: new opportunities for reformulation, IP strategies, and global market penetration.
For regulators: urgency to design large, multicenter trials and evaluate emergency-use pathways.
Risks: local bleeding, optimal dosing still undefined, need for more robust safety data.
Law of Action / Call to Action
Immediate steps include:Funding global phase III trials across diverse populations.
Engaging WHO, FDA, EMA, and national health agencies to prepare conditional frameworks.
Encouraging pharma and biotech to invest in optimized inhaled heparin formulations.
Disseminating early findings to intensivists, pulmonologists, and infectious disease specialists.
BBIU Opinion: Inhaled Heparin and the Reframing of Pandemic Therapy
The Melbourne-led trial on inhaled unfractionated heparin in COVID-19 patients forces us to reconsider the architecture of pandemic response. For decades, crisis medicine has been dominated by a high-cost, high-technology pipeline: monoclonal antibodies, proprietary antivirals, and complex ICU interventions. What this study shows is that a generic, century-old anticoagulant, delivered through a simple nebulizer, can reduce mortality and intubation by nearly half.
The implications are structural. Heparin represents a polyfunctional molecule: anticoagulant, anti-inflammatory, antiviral decoy, and endothelial protector. By targeting multiple pathological cascades at once, it bypasses the fragmentation of modern drug development, where each molecule is engineered for a single pathway and marketed at monopolistic prices. Inhaled heparin reopens the question of whether global health can be rebuilt on repurposed generics with clever delivery systems, instead of chasing exclusivity-driven innovation.
Strategically, this also reframes preparedness. A therapy that is cheap, stockpiled worldwide, and easily reformulated into an inhalable solution can be deployed in low-resource settings far faster than bespoke biologics. It undermines the symbolic and financial dominance of Big Pharma’s pandemic model and restores sovereignty of treatment to health systems otherwise trapped in asymmetric dependency.
In short, inhaled heparin is not just a medical intervention — it is a symbolic countermeasure: old knowledge reactivated against both viral pathology and the economic structures that monopolize cures.
Annexes – Inhaled Heparin and COVID-19
A. COVID-19 Today: Variants and Treatments
Five years after its first appearance, COVID-19 has not disappeared. It has evolved. The virus that once overwhelmed health systems in 2020 is still circulating globally, but in altered form. The currently predominant lineage is NB.1.8.1, a descendant of Omicron, now responsible for over 80% of cases in South Korea and rising in other regions. Like its predecessors, NB.1.8.1 is highly transmissible, but its clinical footprint is shaped by accumulated immunity, vaccines, and therapeutic tools.
Treatment options have expanded, but they remain fragmented and imperfect:
Antivirals like nirmatrelvir/ritonavir (Paxlovid), remdesivir, and molnupiravir, which reduce viral replication when given early, though with limitations (drug interactions, resistance, narrow treatment windows).
Corticosteroids, particularly dexamethasone, which blunt the inflammatory storm but also suppress immune defenses.
Immunomodulators, such as tocilizumab, used when hyperinflammation threatens to destroy lung tissue.
Systemic anticoagulation, to mitigate the clotting abnormalities that distinguish severe COVID-19 from ordinary viral pneumonia.
Supportive care, from oxygen supplementation to invasive ventilation.
Each of these therapies addresses a single pathway: antivirals target replication, steroids dampen inflammation, anticoagulants limit clotting. Yet the disease is multi-dimensional, a convergence of viral injury, immune dysregulation, endothelial collapse, and microthrombosis.
This is the background against which inhaled heparin emerges: not as a replacement, but as a multi-purpose bridge, a drug that can speak the “plural language” of COVID pathology.
Why “NB.1.8.1”? The Logic of SARS-CoV-2 Variant Names
Viruses mutate constantly. To track these changes, scientists use a phylogenetic naming system that reflects ancestry — much like a family tree.
The system most widely used for SARS-CoV-2 is PANGO lineages (short for “Phylogenetic Assignment of Named Global Outbreak lineages”).
Each new branch of the tree gets a label:
“N” refers to a parent lineage originally derived from Omicron.
“NB” indicates a sub-branch of N that accumulated distinct mutations.
“.1” signals the first identified child of NB.
“.8” marks the eighth branch of NB.1.
“.1” at the end shows this is the first identified descendant of NB.1.8.
So NB.1.8.1 means:
A descendant of NB.1.8,
Which itself is a descendant of NB.1,
Which ultimately descends from Omicron (the most mutation-rich and persistent lineage of SARS-CoV-2).
Why This Matters Clinically
Naming = Tracking. Without such precise nomenclature, global health agencies couldn’t trace where a variant emerged, how it spreads, and whether it carries immune escape or severity signals.
NB.1.8.1 is dominant today (Sep 2025) because it has mutations that favor transmissibility over competing Omicron sub-lineages.
Unlike the WHO “Greek letters” (Alpha, Delta, Omicron), which are simplified for public communication, the PANGO system provides granular resolution — essential for virologists, regulators, and pharmaceutical companies adjusting vaccines.
Symbolic Layer
The very existence of NB.1.8.1 shows how the pandemic has moved into a “slow-burn evolutionary phase”: no longer headline-grabbing “Delta vs Omicron,” but a constant churn of minor descendants. The battle is no longer between named titans, but within a crowded family tree of Omicron children — a reminder that the virus adapts faster than political or industrial responses.
B. Heparin Beyond Anticoagulation
Heparin is best known as a blood thinner, discovered in 1916 and standardized for clinical use by the 1930s. It prevents clot formation by accelerating the action of antithrombin, which disables thrombin and factor Xa, two central actors in the clotting cascade. In intravenous or subcutaneous form, it is indispensable in surgery, dialysis, heart attacks, and pulmonary embolism.
But heparin is more than a single-pathway agent:
Anti-inflammatory: By binding cytokines like IL-8 and blocking adhesion molecules such as selectins, it reduces the recruitment of inflammatory cells into injured tissue. In the lung, this may mean fewer neutrophils flooding alveoli, fewer enzymes released to damage membranes, less scarring.
Antiviral decoy: Viruses often hijack heparan sulfate proteoglycans on cell surfaces to anchor themselves before entering. Exogenous heparin can serve as a decoy, binding viral proteins — including the SARS-CoV-2 spike — and preventing cellular entry.
Endothelial protection: Heparin interacts with the glycocalyx, the delicate sugar coat lining blood vessels. By preserving this structure, it reduces vascular leak and capillary fragility.
Anti-fibrotic: Heparin interferes with TGF-β and other growth factor pathways, potentially slowing or preventing the fibrotic remodeling that turns inflamed lungs into rigid, scarred organs.
Neutralization of NETs (neutrophil extracellular traps): By binding to extracellular histones, heparin reduces the toxic debris generated by immune overactivation in severe infections.
The molecule is a polyfunctional scaffold, acting simultaneously in coagulation, inflammation, virology, and tissue repair. This breadth of action is rare, and it is precisely what makes it valuable in complex, multi-system diseases like COVID-19.
Origin and Immunogenicity of Heparin
Heparin is one of the oldest and most widely used drugs in medicine, but its true nature is often misunderstood. To appreciate both its power and its safety profile, we need to look at where it comes from, how it is produced, and why its immune risks are very specific.
Heparin in Nature: A Proteoglycan
Inside the human body, heparin is not floating around as a free drug. It is stored in mast cells — immune cells that sit in connective tissues, especially near blood vessels. In this natural setting, heparin exists as part of a proteoglycan called serglycin.
A proteoglycan is a protein core decorated with long chains of sugars known as glycosaminoglycans (GAGs).
In mast cells, those GAG chains are heparin.
Because of the protein core, this natural form is potentially immunogenic — proteins are the immune system’s favorite targets.
Pharmaceutical Heparin: A Purified Sugar Chain
The heparin used in hospitals is very different from its natural storage form.
It is not a proteoglycan. The protein core is removed during industrial extraction.
What remains are only the sugar chains — the highly sulfated polysaccharides that give heparin its anticoagulant effect.
Industrial production relies mostly on porcine intestinal mucosa (pig intestines), collected at large scale.
The mucosa is digested with enzymes, then heparin is extracted, fractionated, purified, and converted into a sterile drug substance.
The result is pharmaceutical heparin sodium or calcium — a pure glycosaminoglycan, without any protein.
There are two main forms:
Unfractionated heparin (UFH): a mix of long sugar chains, heterogeneous, short half-life, requires monitoring.
Low molecular weight heparin (LMWH): derived from UFH by controlled depolymerization, shorter chains, more predictable pharmacology.
Immunogenicity: Where the Real Risk Lies
Because pharmaceutical heparin is just sugar chains, its intrinsic antigenicity is very low. Sugars of this kind do not usually trigger strong immune responses on their own.
The main immune risk comes from a very specific phenomenon: Heparin-Induced Thrombocytopenia (HIT).
When heparin enters the bloodstream, it can bind to platelet factor 4 (PF4), a protein released by platelets.
Together, they form a new complex that the immune system recognizes as foreign.
Some patients develop IgG antibodies against this complex.
The antibodies then activate platelets, leading to the paradoxical picture:
Low platelet counts (thrombocytopenia).
Dangerous new blood clots (thrombosis), even while the patient is being treated with an anticoagulant.
The risk of HIT is higher with UFH (1–5% of exposed patients) and lower with LMWH (0.5–1%).
What About Inhaled Heparin?
With inhaled heparin, systemic absorption is much lower than with injections. That means the chance of forming PF4–heparin complexes is greatly reduced. To date, no major safety signals have been reported in inhalation studies. Still, careful monitoring of platelet counts is recommended in any clinical trial.
Key Takeaway
In nature, heparin is part of a proteoglycan — sugar chains attached to a protein core. The protein makes it immunogenic.
In medicine, heparin is purified — only the sugar chains remain. By itself, it is poorly immunogenic.
The real immune danger is not the sugar, but the complex with PF4, which can trigger HIT.
Inhaled formulations reduce systemic exposure, making HIT far less likely.
C. Can Heparin Reach the Alveoli? The Delivery Question
Heparin is a large, negatively charged polysaccharide, with a molecular weight of 15–20 kDa for unfractionated heparin (UFH) and 4–6 kDa for low-molecular-weight heparin (LMWH). Normally, such macromolecules do not easily cross biological membranes. But inhalation changes the rules.
When nebulized into a fine mist, heparin particles are deposited along the bronchial tree and in the alveolar sacs. There, they act directly on the surface of epithelial and endothelial cells. Systemic absorption is limited — which is precisely why inhalation is attractive: local action without systemic bleeding.
The choice of formulation matters:
UFH is the most common in inhaled trials. Its large size helps it stay in the lung compartment, acting locally while avoiding significant plasma levels.
LMWH could, in theory, provide more predictable bioavailability and allow systemic monitoring via anti-Xa activity. But its smaller size increases the risk of systemic bleeding, undercutting the advantage of inhalation.
The paradox is clear: the very property that limits heparin’s absorption when injected — its size and charge — becomes an asset when the goal is local action in the lung.
D. Clinical Evidence to Date
Several studies have tested inhaled heparin in respiratory illness:
ARDS and acute lung injury: Trials using nebulized UFH (5,000–25,000 IU per dose) showed reductions in markers of lung injury and trends toward improved oxygenation.
Brazilian enriched UFH trial (2024): Patients received 12.5 mg of enriched UFH (≈10,000–15,000 IU) in 5 mL saline, every 4 hours for 7 days. Results showed improved oxygenation and reduced intubation rates.
Meta-protocols (INHALE-HEP): Multicenter international studies involving ~500 patients reported a ~50% reduction in the composite endpoint of intubation or death compared with standard care.
Safety data so far are reassuring: systemic coagulation parameters remain largely unchanged, and major bleeding events are rare.
E. Tentative Protocol Proposal — INHALE-HEP-COMP
Title
Randomized, double-dummy, blinded trial of inhaled unfractionated heparin, inhaled LMWH, and antiviral standard of care in hospitalized, non-intubated COVID-19 adults with comparable baseline anti-SARS-CoV-2 IgG
Design
Phase II/III, multicenter, randomized, 3-arm, double-dummy, double-blind
Allocation: 1:1:1
Duration: 28-day primary endpoint, safety/PRO follow-up Day 60/90
Blinding strategy: Centrally packaged, barcoded kits (daily kits with IV + neb). Barcode-scanning IRT system allocates correct kit per subject. Placebos organoleptically matched. Independent Clinical Events Committee (CEC) blinded to all allocations adjudicates endpoints.
Population
Inclusion
Adults 18–65, PCR/antigen-confirmed SARS-CoV-2 (NB.1.8.1 or related Omicron sublineage)
Hospitalized, not intubated, requiring low/medium-flow oxygen (SpO₂ ≤94% ambient)
Symptom onset ≤7 days or admission ≤3 days
Comparable baseline anti-S/anti-RBD IgG (central lab stratification by quartiles)
Exclusion
Need for IMV/ECMO at baseline
Major comorbidities (severe COPD, CHF, insulin-dependent DM, CKD ≥G3b, cirrhosis ≥Child B, BMI ≥35)
High bleeding risk, recent hemorrhage, platelets <120k, INR >1.5
History/suspicion of HIT
Pregnancy/lactation
Systemic anticoagulation (therapeutic) within 48h
Interventions
Arm A — Inhaled UFH
12.5 mg UFH (~10–15k IU) in 5 mL saline via nebulizer (mesh/jet, MMAD 1–3 μm)
q4h while awake (4–5 doses/day) × 7 days
Monitoring: aPTT (expected baseline), daily platelets, optional anti-Xa
Arm B — Inhaled LMWH
Enoxaparin 6–10 mg nebulized in 4–5 mL q6h × 7 days
PD-guided: peak anti-Xa target ≤0.20 IU/mL; titration ±2 mg if >0.20 IU/mL
Monitoring: anti-Xa (Day 1, 3), aPTT, daily platelets, bleeding surveillance
Arm C — Antiviral SOC (Remdesivir)
200 mg IV Day 1, then 100 mg IV daily Days 2–5
Inhalation placebo matched to arms A/B
All arms: oxygen protocol, dexamethasone if indicated, uniform VTE prophylaxis SC (unless systemic anti-Xa >0.20 IU/mL), supportive care
Primary Endpoint
Time to sustained clinical deterioration (≥24h) through Day 28:
First initiation of HFNC, NIV, or IMV, or
All-cause death
Events centrally adjudicated by blinded CEC
Key Secondary Endpoints
All-cause mortality Day 28
IMV-free days to Day 28
PaO₂/FiO₂ change at 48–72h
Time to ≥2-point improvement in WHO ordinal scale (Day 14/28)
Safety: ISTH major bleeding, HIT (PF4 ELISA + functional), anti-Xa kinetics
Exploratory: viral load kinetics (Ct D1,3,7), biomarkers (D-dimer, IL-6, NETs, syndecan-1), hospital/ICU stay, long-COVID PROs D60/90
Randomization & Stratification
Central randomization, 1:1:1
Stratification: site, IgG quartile, days from symptom onset (≤3 vs >3–7), age (≤50 vs >50)
Sample Size (illustrative)
Control event rate ~25% (SOC)
Detect HR 0.65 (UFH vs SOC) with 90% power, α=0.05, multiplicity control (Hochberg)
N ≈ 900 (≈300/arm) with one interim (50% events) for efficacy/futility (O’Brien-Fleming)
Safety Oversight
DSMB independent; stopping for bleeding, HIT, futility/efficacy
Daily platelet counts in all arms
Anti-Xa monitored per protocol (mandatory LMWH arm; dummy sampling in others to protect blinding)
Pre-specified pause if >5% LMWH patients show sustained anti-Xa >0.30 IU/mL or bleeding RR >2.0
IMP Management (to sustain blinding)
Centrally packaged double-dummy kits (daily): barcoded, sealed, organoleptically matched
All subjects receive both IV + inhalation (active or placebo)
Barcode scan-to-dose system prevents dispensing errors and records accountability
Sites do not reconstitute; pharmacy handling eliminated
Emergency unblinding via IRT only
Rationale
UFH inhaled: maximizes local lung action with minimal systemic spillover
LMWH inhaled: higher bioavailability, controlled by anti-Xa monitoring
SOC remdesivir: relevant comparator arm
IgG-matched population: reduces variability and strengthens signal attribution
Kit-based double-dummy: sustains rigorous blinding despite different routes
F. Why It Matters
The story of inhaled heparin is not just about COVID-19. It points to a broader principle: that multi-pathway, generic molecules can rival or surpass high-priced innovations if delivery systems are reimagined. It is a lesson in medical sovereignty, economic realism, and scientific humility: sometimes the most powerful tools are the ones already in our hands, waiting to be redeployed.
